Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Middle East Pharmaceutical Industries Co PS Ratio?
Middle East Pharmaceutical Industries CoSAU:4016 -0.86%22 PS Ratio is 4.09 as of Jul. 29, 2026, which is 30% below its 10-year median of 5.83. GuruFocus rates SAU:4016 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 953 Drug Manufacturers companies, Middle East Pharmaceutical Industries Co ranks worse than 68.31% on this metric.
Middle East Pharmaceutical Industries Co (SAU:4016) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Middle East Pharmaceutical Industries Co PS Ratio Related Terms
Middle East Pharmaceutical Industries Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Middle East Pharmaceutical Industries Co PS Ratio Chart
Middle East Pharmaceutical Industries Co Annual Data
Trend
Dec23
Dec24
Dec25
PS Ratio
0.00
6.18
4.83
Middle East Pharmaceutical Industries Co Quarterly Data
For the Drug Manufacturers - Specialty & Generic subindustry, Middle East Pharmaceutical Industries Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Middle East Pharmaceutical Industries Co PS Ratio vs Drug Manufacturers Industry
Middle East Pharmaceutical Industries Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Middle East Pharmaceutical Industries Co's Share Price of today is ﷼57.65. Middle East Pharmaceutical Industries Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼14.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Middle East Pharmaceutical Industries Co (SAU:4016) has a PS Ratio of 4.09 as of Jul. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Middle East Pharmaceutical Industries Co and its competitors. This is 30% below median its historical median of 5.83. Over the past decade, Middle East Pharmaceutical Industries Co's PS Ratio has ranged from 3.96 to 7.68. According to the industry distribution chart, Middle East Pharmaceutical Industries Co ranks #651 out of 953 companies in the Drug Manufacturers industry, placing it in the top 68.3%.
Is Middle East Pharmaceutical Industries Co's PS Ratio too high?
Middle East Pharmaceutical Industries Co's current PS Ratio of 4.09 is 30% below median its 10-year median of 5.83. Over the past 10 years, this metric has ranged from a low of 3.96 to a high of 7.68. The Drug Manufacturers industry median PS Ratio is 2.28. Middle East Pharmaceutical Industries Co's value of 4.09 is 79.4% above this industry median. Based on the distribution chart, Middle East Pharmaceutical Industries Co ranks #651 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Middle East Pharmaceutical Industries Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Middle East Pharmaceutical Industries Co's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Middle East Pharmaceutical Industries Co ranks #651 out of 953 companies for PS Ratio. This places Middle East Pharmaceutical Industries Co in the lower half of its industry. The industry median PS Ratio is 2.28. Middle East Pharmaceutical Industries Co's value of 4.09 is 79.4% above this benchmark. Historically, Middle East Pharmaceutical Industries Co's own PS Ratio has ranged from 3.96 to 7.68 over the past decade. While the company's 10-year median is 5.83 vs. the industry median of 2.28, Middle East Pharmaceutical Industries Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.28, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Middle East Pharmaceutical Industries Co's current PS Ratio of 4.09 is 79.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Middle East Pharmaceutical Industries Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Middle East Pharmaceutical Industries Co's current PS Ratio is 4.09, which is 30% below median its own 10-year median of 5.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Middle East Pharmaceutical Industries Co stock overvalued right now?
Middle East Pharmaceutical Industries Co (SAU:4016) has a current PS Ratio of 4.09. The current PS Ratio is 4.09, which is 30% below median its 10-year median of 5.83 and 79.4% above the Drug Manufacturers industry median of 2.28. Middle East Pharmaceutical Industries Co's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Middle East Pharmaceutical Industries Co (SAU:4016), the current PS Ratio is 4.09 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Middle East Pharmaceutical Industries Co Business Description
Middle East Pharmaceutical Industries Co is a holding company engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments. Geographically, it generates the majority of its revenue from Saudi Arabia.
22GF Score
Get the complete analysis for SAU:4016
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4016 has been successfully added to your 
